Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Dedication - p. v 6. List of Contributors - p. vii 7. Preface - p. xi 8. Acknowledgements - p. xiii 9. Section I. Background Testing - p. xiii 10. Chapter 1. The Molecular Biology of HER2 and HER2-Targeted Therapies - p. 1 11. Chapter 2. HER2 Testing in the Era of Changing Guidelines - p. 13 12. Section II. Advanced Disease - p. 39 13. Chapter 3. Optimal First-Line Treatment of Advanced HER2-Positive Breast Cancer - p. 41 14. Chapter 4. HER2-Positive Breast Cancer: Second Line and Beyond - p. 63 15. Chapter 5. Central Nervous System Metastases in HER2-Positive Breast Cancer - p. 75 16. Chapter 6. Neoadjuvant Treatment of HER2-Positive Breast Cancer—A Review - p. 95 17. Chapter 7. Adjuvant Therapy - p. 107 18. Chapter 8. Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Co-expressing Tumors: Overview of Clinical Practical Implications and Treatment Strategies - p. 119 19. Chapter 9. Deescalating Treatment in the Adjuvant Setting in Low-Risk HER2-Positive Breast Cancer - p. 135 20. Section III. Toxicity Considerations - p. 142 21. Chapter 10. Cardiac Toxicity of HER-2 Targeted Regimens - p. 143 22. Chapter 11. Noncardiac Toxicity of HER2-Targeted Therapy - p. 171 23. Section IV. Therapies on the Horizon - p. 178 24. Chapter 12. Novel Non–HER2-targeted Therapies in HER2+ Breast Cancer - p. 179 25. Chapter 13. Harnessing the Immune System in HER2+ Disease - p. 213 26. Chapter 14. Biosimilars for HER2-Positive Breast Cancer - p. 231 27. Index - p. 239
No hay muestra disponible
No hay ficha técnica disponible
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Dedication - p. v 6. List of Contributors - p. vii 7. Preface - p. xi 8. Acknowledgements - p. xiii 9. Section I. Background Testing - p. xiii 10. Chapter 1. The Molecular Biology of HER2 and HER2-Targeted Therapies - p. 1 11. Chapter 2. HER2 Testing in the Era of Changing Guidelines - p. 13 12. Section II. Advanced Disease - p. 39 13. Chapter 3. Optimal First-Line Treatment of Advanced HER2-Positive Breast Cancer - p. 41 14. Chapter 4. HER2-Positive Breast Cancer: Second Line and Beyond - p. 63 15. Chapter 5. Central Nervous System Metastases in HER2-Positive Breast Cancer - p. 75 16. Chapter 6. Neoadjuvant Treatment of HER2-Positive Breast Cancer—A Review - p. 95 17. Chapter 7. Adjuvant Therapy - p. 107 18. Chapter 8. Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Co-expressing Tumors: Overview of Clinical Practical Implications and Treatment Strategies - p. 119 19. Chapter 9. Deescalating Treatment in the Adjuvant Setting in Low-Risk HER2-Positive Breast Cancer - p. 135 20. Section III. Toxicity Considerations - p. 142 21. Chapter 10. Cardiac Toxicity of HER-2 Targeted Regimens - p. 143 22. Chapter 11. Noncardiac Toxicity of HER2-Targeted Therapy - p. 171 23. Section IV. Therapies on the Horizon - p. 178 24. Chapter 12. Novel Non–HER2-targeted Therapies in HER2+ Breast Cancer - p. 179 25. Chapter 13. Harnessing the Immune System in HER2+ Disease - p. 213 26. Chapter 14. Biosimilars for HER2-Positive Breast Cancer - p. 231 27. Index - p. 239
No hay muestra disponible
No hay ficha técnica disponible
